Peritoneal Surface Oncology

Peritoneal surface oncology is a specialized field of cancer medicine focused on tumors that grow on the peritoneum, the thin membrane lining the abdomen and covering its organs. It combines aggressive surgery to remove visible tumor (cytoreductive surgery) with heated chemotherapy delivered directly into the abdomen (HIPEC) to treat microscopic disease left behind. Centers practicing this specialty treat peritoneal mesothelioma, appendiceal cancers, ovarian cancer, and peritoneal spread from colorectal cancer.

Origin

The field emerged in the late 1980s and 1990s through the work of Dr. Paul Sugarbaker at the Washington Cancer Institute, whose protocols for combining cytoreductive surgery with intraperitoneal chemotherapy transformed previously fatal peritoneal cancers into treatable diseases. The term reflects the recognition that the peritoneal surface is a distinct oncologic compartment requiring its own surgical and chemotherapeutic approach.

Significance in Asbestos Context

For patients diagnosed with peritoneal mesothelioma, the form of asbestos-caused cancer that grows in the abdominal lining, being treated at a peritoneal surface oncology center can meaningfully change prognosis. Cytoreductive surgery with HIPEC has produced median survivals of 5 years or longer in selected patients, compared with roughly 12 months with chemotherapy alone. Because most general oncologists see few or no peritoneal mesothelioma cases in a career, patients should ask for referral to a high-volume peritoneal surface oncology program before starting treatment, since eligibility for surgery can be affected by prior therapies. Treatment records from these specialized centers, including operative notes describing the Peritoneal Cancer Index and completeness of cytoreduction, also become important medical documentation in a legal claim.

Example Sentence

After her peritoneal mesothelioma diagnosis, she was referred to a peritoneal surface oncology program where the surgical team evaluated her for cytoreductive surgery with HIPEC.

Related Terms

Peritoneal Mesothelioma, Cytoreductive Surgery, HIPEC, Peritoneal Cancer Index, Sugarbaker Procedure, Intraperitoneal Chemotherapy

Notes

• Ask for referral to a high-volume peritoneal surface oncology center (such as MD Anderson, Moffitt, Memorial Sloan Kettering, Wake Forest, Mercy Medical Center in Baltimore, or Washington Cancer Institute) before starting systemic chemotherapy, since prior treatment can affect surgical candidacy.
• Request that imaging (CT, MRI, or PET) and any prior biopsy slides be sent to the specialty center for independent review. Peritoneal mesothelioma is frequently misdiagnosed on initial pathology.
• Preserve all operative reports, pathology reports, and HIPEC treatment records; these document disease extent and response and are directly relevant to both ongoing care and any legal claim.
• Ask the surgical team to explain your Peritoneal Cancer Index (PCI) score and Completeness of Cytoreduction (CC) score, as these strongly predict outcome and guide follow-up.